AR882, selective uric acid transporter 1 (URAT1) inhibitor in development, completed a phase 2, 140 pt 12-week PBO controlled trial, where 75 mg/d lowered SUA by 59% (8.6 to 3.5 ) & 42% (8.6 to 5.0 ) in 50 mg dose group - all better than PBO https://t.co/HHzHWj4XQr https://t.co/gJD9hnkFJc